Lyla is an Associate in our San Francisco Bay Area office. She joined SR One in 2024, bringing a background in biotechnology and therapeutics equities. Prior to SR One, she was an Associate Analyst at Hudson Bay Capital, covering therapeutics. Previously, she served as a Vice President in Biotech Equity Research at TD Cowen and worked in equity research at Oppenheimer & Co. She has also held roles with Columbia University’s Translational Therapeutics Accelerator and Columbia Tech Ventures, contributing insight across various stages of development.
Lyla holds a Ph.D. in Microbiology & Immunology from Columbia University and a B.A. in Biological Sciences and Economics from Cornell University.